ERBB2 and non-small cell lung carcinoma: DESTINY-Lung04, a phase III trial of trastuzumab deruxtecan in the first line in unresectable or metastatic NSCLC with HER2 exon 19 or 20 mutations is ongoing (NCT0504879) and will potentially provide additional insight into this line of treatment.